Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients

Journal of Immunotherapy
C BottaPierpaolo Correale

Abstract

Cetuximab is a human-murine chimeric monoclonal antibody to the epidermal growth factor receptor, active for advanced colorectal cancer treatment in combination with chemotherapy. Cetuximab mainly acts by inhibiting epidermal growth factor receptor-mediated pathways in cancer cells; however, in the human host, its IgG1 backbone may offer additional antitumor activity that includes FcγRs-mediated antibody-dependent cell cytotoxicity, phagocytosis, cross priming, and tumor-specific T-cell-mediated immune response. These mechanisms are still under active investigation. At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase II trial aimed to test the toxicity and the biological and antitumor activity of a novel biochemotherapy regimen combining polychemotherapy with gemcitabine, irinotecan, levofolinic acid, and fluorouracil with cetuximab and with subcutaneous low-dose metronomic aldesleukin (GILFICet regimen). The peripheral blood mononuclear cells of the first 20 patients enrolled in the GILFICet trial were collected at baseline and after 6 treatment cycles and examined for immune-phenotype change by flow cytometry. Colon cancer-specific T-cell lines were al...Continue Reading

Citations

Dec 18, 2012·Immunotherapy·José Medina-Echeverz, Pedro Berraondo
Apr 14, 2015·Seminars in Cancer Biology·W G JiangD Santini
May 23, 2013·Expert Opinion on Biological Therapy·Marco RossiPierosandro Tagliaferri
Jun 3, 2015·Cancer Immunology, Immunotherapy : CII·Maria Grazia CusiPierpaolo Correale
Dec 21, 2016·Immunotherapy·Pierpaolo CorrealePierosandro Tagliaferri
May 8, 2018·Oncotarget·Marco RossiPierfrancesco Tassone
Oct 17, 2019·Frontiers in Oncology·Jesús García-FoncillasSebastian Stintzing
Jun 25, 2016·World Journal of Gastroenterology : WJG·Xiang LiWei-Dong Han
Nov 30, 2019·Frontiers in Oncology·Michele CaragliaPierosandro Tagliaferri
Mar 28, 2020·Molecular Carcinogenesis·Hang RuanJian Yu
Nov 10, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A G Duffy, T F Greten

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.